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MicroRNAs (miRNAs) have been found to be dysregulated in prostate cancer (PCa). In this study, we investigated if
miR-1207-3p is capable of distinguishing between indolent and aggressive PCa and if it contributes to explaining
the disproportionate aggressiveness of PCa in men of African ancestry (moAA). A total of 404 patients with primary
adenocarcinoma of the prostate were recruited between 1988 and 2003 at the Moffitt Cancer Center, Tampa, FL,
USA. Patient clinicopathological features and demographic characteristics such as race were identified. RNA
samples from 404 postprostatectomy prostate tumor tissue samples were analyzed by real-time quantitative
reverse transcription polymerase chain reaction for the mRNA expression of miR-1207-3p. miR-1207-3p
expression in PCa that resulted in overall death or PCa-specific death is significantly higher than in PCa cases
that did not. The same positive correlation holds true for other clinical characteristics such as biochemical
recurrence, Gleason score, clinical stage, and prostate-specific antigen level. Furthermore, miR-1207-3p
expression was significantly less in moAA in comparison to Caucasian men. We also evaluated whether miR-
1207-3p is associated with clinical outcomes adjusted for age at diagnosis and tumor stage in the modeling. Using
competing risk regression, the PCa patients with a high miR-1207-3p expression (≥6 vs 3) had a high risk to
develop PCa recurrence (hazard rate = 2.5, P b .001) adjusting for age at diagnosis and tumor stage. In conclusion,
miR-1207-3p is a promising novel prognostic biomarker for PCa. Furthermore, miR-1207-3p may also be important
in explaining the disproportionate aggressiveness of PCa in moAA.
Translational Oncology (2016) 9, 236–241Introduction
Prostate cancer (PCa), with nearly 240,000 men diagnosed in the
United States in 2014, is a major cause of cancer morbidity andmortality [1–3]. The annual morbidity continues to steadily grow as
the rate of this cancer has increased by 14% over the last two decades
[3–5]. One of the challenges faced in combating PCa is itsNational Cancer Institute grant R01 CA128813 (J. Y. P.).
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Table 1. Correlation of miR-1207-3p PCa Tissue Expression with Clinical Characteristics of PCa
in 404 Patients
Variables N Mean ± SD P
Recurrence Yes 155 6.53 ± 3.75
No 249 4.49 ± 3.54 b .0001
Death Yes 129 7.05 ± 4.37
No 275 4.44 ± 3.09 b .0001
Death specific Alive 273 4.48 ± 3.08
Dead 79 6.85 ± 4.60
PCA specific 50 7.38 ± 4.02 b .0001
Race Black 15 3.00 ± 2.65
White 389 5.36 ± 3.76 .016
Gleason score ≤6 167 4.81 ± 3.40 b .0001
7 135 3.85 ± 2.52
≥8 29 6.33 ± 4.30
Stage 1-2 302 4.84 ± 3.34
3-4 95 6.51 ± 4.44 b .0001
PSA 4 278 3.97 ± 3.79 .002
4-10 168 4.03 ± 2.80
10 51 5.73 ± 3.58
Marital status Divorced 22 3.80 ± 3.05 .154
Married 349 5.37 ± 3.75
Single 22 5.47 ± 3.79
N, number; SD, standard deviation; P, P value. The level of significance was established using a P
value less than .05.
Table 2. PCa Tissue Expression of miR-1207-3p in moAA and CM
Variables N Mean ± SD P
Race Black 15 3.00 ± 2.65
White 389 5.36 ± 3.76 .016
The level of significance was established using a P value less than .05.
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dependent, and initially, most men are responsive to pharmacological
and surgical androgen deprivation therapies [6]. However, in spite of
these efforts, in a subset of patients, the cancer inevitably reoccurs and
advances, with approximately 30% of men developing clinical
recurrence [3]. Ultimately, it is this highly aggressive form of PCa
that leads to death [6]. Therapeutic options for advanced PCa are
currently limited and largely ineffective [7].
Furthermore, for reasons still unclear, men of African ancestry
(moAA) have the worlds’ highest incidence of PCa [8]. moAA have
approximately two-thirds increased incidence and two times the
increased mortality rate compared with Caucasian men (CM) [9,10].
Furthermore, moAA are more frequently diagnosed with worse
clinicopathological features (prostate-specific antigen [PSA] levels,
Gleason grades, advanced tumor stage, etc.) than CM [8,11,12]. To
decrease the excess mortality, effective early detection and therapeutic
strategies are required.
MicroRNAs (miRNAs) have potential as effective early detection
and prognostic biomarkers in PCa [4]. miRNAs are small (18-22
nucleotides) nonprotein coding regulatory RNAs [13]. They are well
conserved and endogenously synthesized and have been shown to
regulate the expression of nearly 60% of human genes [13]. Many
miRNAs have been reported to be implicated in cancer pathogenesis,
functioning as either oncogenes or tumor suppressors according to the
roles of their target genes [13–15]. Their expression is usually found
to be aberrant in many cancers including PCa [1,14,16]. Studies of
different cancers have demonstrated that miRNAs can be useful
tumor markers. For example, specific oncogenic and tumor
suppressor miRNAs have been detected in the serum and urine of
patients with breast, ovarian, and bladder cancer [17–20]. However,
only few reports exist in literature describing the role of miRNAs in
PCa aggressiveness and in PCa racial disparities.
miR-1207-3p is encoded by the PVT1 nonprotein coding gene
located at the 8q24 PCa susceptibility locus [21]. In this study, we
aimed to assess the role of miR-1207-3p in PCa aggressiveness
because aggressive PCa is the life-threatening form of PCa [2]. At
diagnosis, clinical and pathologic features, such as PSA level,
pathologic Gleason grade, and tumor stage, are used to inform
clinical decision making [4,5,22]. To determine if miR-1207-3p can
be useful in PCa clinical decision making, we examined the expression
of miR-1207-3p in prostate tumor tissue of patients by real-time
quantitative reverse transcription polymerase chain reaction (qPCR).
Then, we evaluated the possible prognostic implication of
miR-1207-3p. Consequently, this study investigated the clinical
significance of miR-1207-3p in PCa and determined if it contributes
to explaining the disproportionate aggressiveness of PCa in moAA.
Materials and Methods
Patients and Samples
To evaluate miR-1207-3p expression in clinical samples, we used
tissue specimens from 404 patients (389 CM and 15 moAA) with
primary adenocarcinoma of the prostate from 1988 to 2003 at the
Moffitt Cancer Center, Tampa, FL, USA. Institutional Review Board
approvals were obtained for the study protocol at the University of
South Florida and the Moffitt Cancer Center, Tampa, FL. Signed
informed consent was obtained from all study participants.
Clinicopathological and demographic information of the patients
are summarized in Tables 1 and 2.RNA Extraction and qPCR Analysis
Prostate tumor tissues were collected at prostatectomy from 404
patients with primary PCa. After histopathologic confirmation, PCa
tissues were obtained from unstained slides with macrodissection. Total
RNA was extracted from PCa tissues using superscript IV First-strand
Synthesis system (Life Technology No. 18091200) and quantified using
UV spectrophotometer NanoDrop 2000 (Thermo Scientific, USA). The
cDNA templates were synthesized from RNA samples by SuperScript
using random hexamers. RNA samples from the 404 patient samples
were analyzed by qPCR to examine the expression of miR-1207-3p.
Gene expression was determined using power SYBRGreen Real-Time
PCR Master Mix (Life Technology No. 4367649) and 2.0 μl of cDNA
template. qPCR was performed on an ABI7900 machine using the
following amplification conditions: 10 minutes at 95°C followed by 45
cycles of 15 seconds at 95°C, 30 seconds at 55°C, and 30 seconds at 72°C.
All assays were carried out in triplicate to control for technical variance.
Cycle threshold values were determined using the SDS ver2.3 software
(Bio-Rad). MicroRNA 1207-3p expression was normalized with U6
expression within each sample. Relative quantification of target gene
expression was evaluated using the comparative cycle threshold method.
Statistical Analysis
Differences in two and three clinical outcome groups were compared
using the two-tailed Student’s t test and analysis of variance test,
respectively. For evaluating the association of miR-1207-3p expression
with PCa death and PCa recurrence in CM, a competing risk approach
was applied. miR-1207-3p expression was categorized into three groups:
low (b3), median (3-6), and high (≥6) based on the tertile cut points.
Factors associated with PCa death were evaluated using competing-risk
regression [23]. The cumulative incidence curves of PCa death were
238 miR-1207-3p and Prostate Cancer Das et al. Translational Oncology Vol. 9, No. 3, 2016generated by the subgroups of miR-1207-3p expression. For evaluating
miR-1207-3p expression associated with PCa survival, PCa death was the
primary interest, and non-PCa death was treated as a competing risk.
Survival timewas defined as the time fromdate of PCa diagnosis to date of
death. For evaluating association of miR-1207-3p expression with PCa
recurrence, PCa recurrence was the primary interest, and nonrecurrence
death was treated as a competing risk. Time to event was defined as time
from the date of PCa diagnosis to PCa recurrence or nonrecurrence death,
whichever comes first. Data were censored at the last follow-up date. The
same approach was applied to evaluate the association of miR-1207-3p
expression with PCa recurrence. The candidate factors taken into
consideration in modeling included age at diagnosis, Gleason score, and
tumor stage. PSA was excluded from the models because the PSA values
were missing in 150 CM. The level of significance was established using a
P value less than .05.Table 3. miR-1207-3p Expressions Associated with PCa Death and Recurrence for CM
Variables PCa Death PCa Recurrence
Factor Unadjusted Adjusted Unadjusted Adjusted
HR (95% CI) 1 HR (95% CI) 1 HR (95% CI) 1 HR (95% CI) 1
N = 378 N = 368
Age at diagnosis
(in 10 years)
1.9 (1.2-2.9) ** 1.9 (1.2-3.0) ** 1.1 (0.9-1.4) 0.9 (0.8-1.2)
Stage (3/4 vs 1/2) 1.5 (0.8-2.6) 1.3 (0.7-2.4) 3.1 (2.2-4.3) ** 2.7 (1.9-3.8) **
miR-1207-3p b3 1 1 1 1
3-6 1.0 (0.4-2.6) 1.0 (0.4-2.7) 1.2 (0.8-2.0) 1.3 (0.8-2.1)
≥6 2.1 (0.9-4.6) 1.8 (0.8-4.3) 2.7 (1.8- 4.2) ** 2.5 (1.6-4.0) **
1 Hazard rate (95% confidence interval) analyzed using competing risk regression.
* P b 0.05.
** P b 0.01.Results
Positive Correlation between miR-1207-3p Expression and
Clinicopathological Features of PCa
To determine miR-1207-3p expression pattern in PCa and to
investigate its ability to predict clinical progression (e.g., biochemical
recurrence, PCa-specific death, etc.), miR-1207-3p expression
pattern in PCa tissues was analyzed using tissues collected from
404 primary PCa patients at the Moffitt Cancer Center. Correlations
between miR-1207-3p expression and known clinical and patholog-
ical parameters were determined. We observed that increased
miR-1207-3p expression in PCa tissue is significantly positively
associated with aggressive clinicopathological features. As shown in
Table 1, miR-1207-3p overexpression is positively correlated with
overall death and PCa-specific death in patients with PCa.
miR-1207-3p expression in PCa tissues of patients that died from
any cause (7.05 ± 4.37 vs 4.44.18 ± 3.09, P b .0001) or experienced
PCa-specific death (7.38 ± 4.02 vs 4.48 ± 3.08, P b .0001) is
significantly higher than expression in PCa tissues of patients that
remained alive. Next, we investigated the expression of miR-1207-3p
in PCa tissues of patients that had recurrent versus those that had
nonrecurrent PCa to explore the involvement of miR-1207-3p in
PCa progression. We observed that the expression of miR-1207-3p is
significantly higher in recurrent PCa in comparison to nonrecurrent
PCa (6.53 ± 3.75 vs 4.49 ± 3.54, P b .0001). This indicates that
miR-1207-3p overexpression is associated with progression of PCa
patients and may serve as a novel prognostic biomarker for PCa.
Indeed, miR-1207-3p is significantly overexpressed in PCa tissues
from patients with a Gleason score ≥8 (6.33 ± 4.30) in comparison to
patients with a Gleason score ≤6 (4.81 ± 3.40) or Gleason score 7
(3.85 ± 2.52, P ≤ .0001), further confirming miR-1207-3p as a
prognostic biomarker in PCa. In addition, miR-1207-3p expression’s
positive correlation with advanced disease was also borne out for PCa
stage (stage 1-2: 4.84 ± 3.34 vs stage 3-4: 6.51 ± 4.44, P b .0001) and
PSA levels (PSA levels b4: 3.97 ± 3.79, vs PSA levels 4-10: 4.03 ± 2.80 vs
PSA levels N10: 5.73 ± 3.58,P = .002). To our knowledge, this is the first
observation of miR-1207-3p as a prognostic biomarker in PCa.
miR-1207-3p Is Differentially Expressed in PCa in moAA
compared with CM
It is noteworthy that, in this cohort, moAA had a significantly
decreased expression of miR-1207-3p in their PCa tissues in
comparison to miR-1207-3p expression in the PCa tissue of CM.miR-1207-3p expression was significantly less in PCa tissues of
moAA in comparison to the PCa tissues of CM (3.00 ± 2.65 vs 5.36 ±
3.76, P = .016) (Table 2). This suggests that miR-1207-3p may play a
role in explaining the disproportionately increased aggressiveness of
PCa in moAA.
miR-1207-3p Expression Is Associated with PCa Recurrence
and PCa-Specific Death in CM
Among CM, there are 118, 131, and 140 patients with a low (b3),
median (3-6), and high (≥6) miR-1207-3p expression, respectively.
In addition to miR-1207-3p expression, the candidate factors taken
into consideration in modeling included age at diagnosis, Gleason
score, and tumor stage. Age at diagnosis significantly correlated with
PCa-specific death (hazard rate [HR] = 1.9, P b .01). As expected,
stage is significantly correlated with recurrence (HR = 2.7, P b .01).
Although Gleason score values for some patients were missing
(missing n = 71 in CM), Gleason score was nevertheless highly
correlated with tumor stage (Fisher’s exact P value b .001). We
evaluated the association of miR-1207-3p with clinical outcomes
adjusting for age at diagnosis and tumor stage in the modeling. Using
competing risk regression, the CM with a high miR-1207-3p
expression (≥6 vs 3) had a high risk of developing PCa recurrence
(HR = 2.5, P b .001) adjusting for age at diagnosis and tumor stage.
Also, miR-1207-3p expression had a marginally significant impact on
PCa survival (HR = 1.8 P = .06) (Table 3, Figures 1 and 2).
Discussion
Approximately 30% of PCa patients develop clinical recurrence, and
the survival period of this phase of PCa is limited and extremely
variable [3]. The challenge lies in the identification of those patients
most at risk for relapse. Currently, factors such as serum PSA level,
Gleason score, and tumor stage are used for diagnosis, prognostica-
tion, and treatment decision making [4,24]. However, none of these
alone or in combination are adequate indicators for accurate clinical
decision making [3]. It is likely that heterogeneity of PCa at the
molecular level may account for the fact that even those patients
displaying similar PSA levels, tumor stage, and Gleason score can still
have different clinical outcomes [3]. Furthermore, current measures
for predicting/detecting recurrence such as increased serum PSA levels
may actually lead to false-positive diagnosis [25]. Moreover, increased
PSA following radical prostatectomy can be caused by the presence of
residual benign prostate tissue [3]. These issues with the use of PSA
are considered so problematic that the US Preventive Services Task
Force has advised against the widespread use of PSA based on their
Figure 1. Cumulative incidence of PCa death by miR-1207-3p expression level (P = .062).
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cause more harm than good [26]. Consequently, further understand-
ing of the molecular abnormalities underlying PCa progression is
critical to the discovery of good molecular biomarkers for diagnosis,
prognostication, and clinical decision making.
Understanding the molecular mechanisms of PCa progression is
essential for the discovery of robust prognostic markers which are
capable of helping to identify those patients that are at the greatest risk
of relapse. This will, in turn, enable us to optimize management
strategies to control PCa progression. In recent studies, several
putative biomarkers have been suggested which, thus far, have only
achieved limited success. Among them are prostate cancer antigen 3,
prostate-specific membrane antigen, and altered expression of
apoptotic regulators Bcl-2 and Bax [7,24,27]. These proposed
prognostic biomarkers either have not been validated in multiple
studies/large scale studies or have failed to reliably and accurately
estimate the clinical outcome due to the heterogeneity of PCa [7].
Considering these current limitations, it remains a priority in PCa
research to discover novel biomarkers to add to our “tool box” toFigure 2. Cumulative incidence of PCa recurrencimprove the clinical decision-making process. Identification of
biomarkers which can efficiently predict recurrence after radical
prostatectomy would be of great clinical significance. Besides, a
biomarker that can predict distinct outcomes regardless of similar
clinical characteristics would be invaluable. To contribute to this
effort, in the present study, we evaluated the expression of
miR-1207-3p in the PCa tissues of patients with both aggressive
and nonaggressive PCa.
The importance of miRNAs in cancer biology has become
apparent in many different cancers, including PCa [14–16].
Typically, they regulate biological processes such as proliferation,
migration, apoptosis, and differentiation by negatively regulating
gene expression at the posttranscriptional level via binding to the 3′
untranslated region of their mRNA target [4,14]. There are several
advantages to the discovery of microRNA prognostic biomarkers
[22]. First, they have been shown to be able to distinguish
differentiation states of several malignancies including breast, lung,
and colon cancers [13,22]. Hence, their aberrant expression can be
exploited as a prognostic tool to distinguish between less aggressivee by miR-1207-3p expression level (P b .001).
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investigations of miRNA differential expression in cancers are proving
to be very beneficial. Second, they are relatively stable in tissues and
upon their release into a variety of biofluids such as blood and urine
[28,29]. Repeated measurements of miRNA levels in biofluids are
very feasible, are minimally invasive, and can provide critical
information on a disease’s molecular signature status over time
through the course of treatment and recurrence [2]. Real-time qPCR
assays are able to detect specific RNAs indicative of disease status from
a simple noninvasive sampling without the need for a biopsy or
surgically resected tissue [2,22]. Consequently, we assessed the role of
miR-1207-3p expression in PCa patients with a focus on a potential
role in prognostication.
Our results demonstrate that it may be possible to predict clinical
behavior of PCa based upon miR-1207-3p expression in primary
PCa. To our knowledge, this is the first study to evaluate the
expression of miR-1207-3p in any human disease. PCa is a
heterogeneous disease, with the exact mechanisms for its development
and progression unclear [30]. However, our data show that the
expression of miR-1207-3p in PCa tissues displays a significant and
distinctly different pattern between indolent and aggressive PCa.
Overexpression of miR-1207-3p is clearly positively related to PCa
progression andworse prognosis. Therefore, our data support the potential
use of miR-1207-3p as a prognostic biomarker in PCa.We anticipate that
this beneficial use will advance into the clinical setting soon.
Despite progress being made in the field, significant PCa racial
disparity persists [26,31,32]. And the aggressiveness of the disease
may be due to specific biological factors [31,32]. Here, we present
data that suggest that miR-1207-3p could possibly contribute to the
disproportionate aggressiveness of miR-1207-3p in moAA. The
discovery of a miRNA biomarker that is capable of distinguishing
between indolent and aggressive PCa and displays differential
expression in men of different ancestry would be of great significance
for the development and optimization of personalized treatment
approaches [33]. Moreover, as moAA have a two-fold higher chance
of getting PCa and aggressive PCa, it is of great importance to
enhance our understanding of the molecular mechanisms which may
explain the disproportionately increased aggressiveness of PCa in
moAA [8,31,32]. Differential expression of miRNAs such as miR-26a
has been reported in PCa [9]. We also previously reported that
miR-21 is associated with recurrence, especially in obese cases [16].
However, the importance of miRNAs in PCa in moAA is still unclear.
In this regard, we have discovered that miR-1207-3p is differentially
expressed in primary tumors of moAA tissues compared with primary
tumors of CM. To our knowledge, this is the first report of a
microRNA that directly correlates with aggressive PCa but has
divergent expression between CM and moAA. These data suggest that
it may be possible to predict clinical behavior of PCa based upon
miRNA-1207-3p expression in primary PCa. We anticipate that this
beneficial use will advance into the clinical setting.
Although the overall sample size of the present study is relatively
large, a limitation is the small sample size of the moAA subgroup.
Although challenging because of issues related to recruitment, a larger
study enriched with a substantial proportion of moAA is warranted.
In addition, the present study did not examine miR-1207-3p
expression in nontumor versus tumor tissues. Therefore, the current
data do not provide information regarding whether miR-1207-3p is
differentially expressed in normal prostate versus PCa tissue.
Likewise, because miRNAs exert functions via regulating theexpression levels of their target genes, it is of great importance to
identify the target genes of miR-1207-3p in PCa and to investigate
the involvement of miR-1207-3p target genes in PCa. Further studies
are needed to address these issues.
Conclusion
Our study identifies miR-1207-3p as a novel prognostic biomarker of
aggressive PCa that is differentially expressed between CM and
moAA. As such, an individual PCa patient’s miR-1207-3p PCa tissue
expression level has the potential to provide a novel and clinically
relevant basis for making decisions in PCa. It is also possible that
miR-1207-3p–based therapeutic strategies may have efficacy in PCa
but must be applied in a personalized fashion. Further studies are
required to establish this.
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